Researchers have identified a key molecular switch that controls how aggressive pancreatic ductal adenocarcinoma becomes and how it responds to treatment.
The study shows that mutant KRAS, the main driver of pancreatic cancer, suppresses GATA6, a gene that helps cancer cells stay more mature and treatment-responsive. When GATA6 is turned off, tumors shift into a more aggressive, treatment-resistant form.
Scientists found that KRAS activates the ERK pathway, which stabilizes a protein called JUNB. JUNB directly shuts down GATA6, pushing tumors into a highly metastatic “basal-like” state. Blocking KRAS or ERK breaks this process, allowing GATA6 to turn back on, making tumors less aggressive and more sensitive to chemotherapy. This discovery supports combining KRAS-targeted drugs with standard chemotherapy to improve outcomes in pancreatic cancer.